These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 30403995)

  • 21. A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity.
    Lai H; Paul AM; Sun H; He J; Yang M; Bai F; Chen Q
    Vaccine; 2018 Mar; 36(14):1846-1852. PubMed ID: 29490880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Convalescent patient-derived monoclonal antibodies targeting different epitopes of E protein confer protection against Zika virus in a neonatal mouse model.
    Niu X; Zhao L; Qu L; Yao Z; Zhang F; Yan Q; Zhang S; Liang R; Chen P; Luo J; Xu W; Lv H; Liu X; Lei H; Yi C; Li P; Wang Q; Wang Y; Yu L; Zhang X; Bryan LA; Davidson E; Doranz JB; Feng L; Pan W; Zhang F; Chen L
    Emerg Microbes Infect; 2019; 8(1):749-759. PubMed ID: 31130109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Zika virus envelope nanoparticle antibodies protect mice without risk of disease enhancement.
    Shukla R; Shanmugam RK; Ramasamy V; Arora U; Batra G; Acklin JA; Krammer F; Lim JK; Swaminathan S; Khanna N
    EBioMedicine; 2020 Apr; 54():102738. PubMed ID: 32305868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structural Basis of Zika Virus Specific Neutralization in Subsequent Flavivirus Infections.
    Sevvana M; Rogers TF; Miller AS; Long F; Klose T; Beutler N; Lai YC; Parren M; Walker LM; Buda G; Burton DR; Rossmann MG; Kuhn RJ
    Viruses; 2020 Nov; 12(12):. PubMed ID: 33255202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Somatic Hypermutation and Framework Mutations of Variable Region Contribute to Anti-Zika Virus-Specific Monoclonal Antibody Binding and Function.
    Tsuji I; Vang F; Dominguez D; Karwal L; Sanjali A; Livengood JA; Davidson E; Fouch ME; Doranz BJ; Das SC; Dean HJ
    J Virol; 2022 Jun; 96(11):e0007122. PubMed ID: 35575481
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope.
    Long F; Doyle M; Fernandez E; Miller AS; Klose T; Sevvana M; Bryan A; Davidson E; Doranz BJ; Kuhn RJ; Diamond MS; Crowe JE; Rossmann MG
    Proc Natl Acad Sci U S A; 2019 Jan; 116(5):1591-1596. PubMed ID: 30642974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dengue and Zika virus infections are enhanced by live attenuated dengue vaccine but not by recombinant DSV4 vaccine candidate in mouse models.
    Shukla R; Beesetti H; Brown JA; Ahuja R; Ramasamy V; Shanmugam RK; Poddar A; Batra G; Krammer F; Lim JK; Kale S; Lal AA; Swaminathan S; Khanna N
    EBioMedicine; 2020 Oct; 60():102991. PubMed ID: 32949997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Zika Virus-Like Particles Bearing a Covalent Dimer of Envelope Protein Protect Mice from Lethal Challenge.
    De Lorenzo G; Tandavanitj R; Doig J; Setthapramote C; Poggianella M; Sanchez-Velazquez R; Scales HE; Edgar JM; Kohl A; Brewer J; Burrone OR; Patel AH
    J Virol; 2020 Dec; 95(1):. PubMed ID: 33028720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective Zika vaccines engineered to eliminate enhancement of dengue infection via immunodominance switch.
    Dai L; Xu K; Li J; Huang Q; Song J; Han Y; Zheng T; Gao P; Lu X; Yang H; Liu K; Xia Q; Wang Q; Chai Y; Qi J; Yan J; Gao GF
    Nat Immunol; 2021 Aug; 22(8):958-968. PubMed ID: 34267374
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutralization of Zika virus by E protein domain III-Specific human monoclonal antibody.
    Kim SI; Kim S; Shim JM; Lee HJ; Chang SY; Park S; Min JY; Park WB; Oh MD; Kim S; Chung J
    Biochem Biophys Res Commun; 2021 Mar; 545():33-39. PubMed ID: 33535104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dengue and Zika Virus Domain III-Flagellin Fusion and Glycan-Masking E Antigen for Prime-Boost Immunization.
    Lin HH; Yang SP; Tsai MJ; Lin GC; Wu HC; Wu SC
    Theranostics; 2019; 9(16):4811-4826. PubMed ID: 31367259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice.
    Ramasamy V; Arora U; Shukla R; Poddar A; Shanmugam RK; White LJ; Mattocks MM; Raut R; Perween A; Tyagi P; de Silva AM; Bhaumik SK; Kaja MK; Villinger F; Ahmed R; Johnston RE; Swaminathan S; Khanna N
    PLoS Negl Trop Dis; 2018 Jan; 12(1):e0006191. PubMed ID: 29309412
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of Dengue/Zika Virus Pathogenicity by Antibody-Dependent Enhancement and Strategies to Protect Against Enhancement in Zika Virus Infection.
    Khandia R; Munjal A; Dhama K; Karthik K; Tiwari R; Malik YS; Singh RK; Chaicumpa W
    Front Immunol; 2018; 9():597. PubMed ID: 29740424
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection.
    Fernandez E; Dejnirattisai W; Cao B; Scheaffer SM; Supasa P; Wongwiwat W; Esakky P; Drury A; Mongkolsapaya J; Moley KH; Mysorekar IU; Screaton GR; Diamond MS
    Nat Immunol; 2017 Nov; 18(11):1261-1269. PubMed ID: 28945244
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Yeast-produced subunit protein vaccine elicits broadly neutralizing antibodies that protect mice against Zika virus lethal infection.
    Zhang W; Qu P; Li D; Zhang C; Liu Q; Zou G; Dupont-Rouzeyrol M; Lavillette D; Jin X; Yin F; Huang Z
    Antiviral Res; 2019 Oct; 170():104578. PubMed ID: 31394119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prior dengue virus serotype 3 infection modulates subsequent plasmablast responses to Zika virus infection in rhesus macaques.
    Singh T; Miller IG; Venkatayogi S; Webster H; Heimsath HJ; Eudailey JA; Dudley DM; Kumar A; Mangan RJ; Thein A; Aliota MT; Newman CM; Mohns MS; Breitbach ME; Berry M; Friedrich TC; Wiehe K; O'Connor DH; Permar SR
    mBio; 2024 Mar; 15(3):e0316023. PubMed ID: 38349142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Zika Virus Envelope Protein and Antibody Complexes.
    Dai L; Wang Q; Song H; Gao GF
    Subcell Biochem; 2018; 88():147-168. PubMed ID: 29900496
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maternally Acquired Zika Antibodies Enhance Dengue Disease Severity in Mice.
    Fowler AM; Tang WW; Young MP; Mamidi A; Viramontes KM; McCauley MD; Carlin AF; Schooley RT; Swanstrom J; Baric RS; Govero J; Diamond MS; Shresta S
    Cell Host Microbe; 2018 Nov; 24(5):743-750.e5. PubMed ID: 30439343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice.
    Sapparapu G; Fernandez E; Kose N; Bin Cao ; Fox JM; Bombardi RG; Zhao H; Nelson CA; Bryan AL; Barnes T; Davidson E; Mysorekar IU; Fremont DH; Doranz BJ; Diamond MS; Crowe JE
    Nature; 2016 Dec; 540(7633):443-447. PubMed ID: 27819683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Defining the impact of flavivirus envelope protein glycosylation site mutations on sensitivity to broadly neutralizing antibodies.
    Contreras M; Stuart JB; Levoir LM; Belmont L; Goo L
    mBio; 2024 Feb; 15(2):e0304823. PubMed ID: 38193697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.